Hyperhidrosis

Hyperhidrosis is sweating beyond what is needed for temperature regulation. Botulinum toxin reduces acetylcholine-mediated signaling to eccrine sweat glands, making this a glandular use rather than a skeletal-muscle treatment. The regulatory and safety questions depend strongly on whether sweating is primary or secondary and which body site is involved.

Primary, Secondary, Focal, and Generalized Sweating

Term	Reference meaning	Why it matters
Primary hyperhidrosis	Excessive sweating without another condition or substance identified as the cause, often in a focal pattern.	This is the disease category represented by the U.S. axillary BOTOX indication.
Secondary hyperhidrosis	Excessive sweating associated with another disease, medication, or physiologic cause.	Symptom suppression should not replace assessment of the underlying cause.
Focal hyperhidrosis	Sweating concentrated in areas such as the axillae, palms, soles, or craniofacial region.	Evidence and functional risks differ by body site.
Generalized hyperhidrosis	Sweating across broad body areas.	A focal product label cannot be extended to a generalized pattern.

The U.S. label specifically advises evaluation for potential causes of secondary hyperhidrosis. “Excessive sweating” alone therefore does not identify the diagnosis, approved product use, or appropriate treatment context.

U.S. Product and Body-Site Status

Product and use	U.S. label status	Boundary
Botox for severe primary axillary hyperhidrosis	FDA-labeled in adults when topical agents provide inadequate management.	The indication is therapeutic BOTOX, not BOTOX Cosmetic.
Botox for palmar hyperhidrosis	Not established in the current U.S. label.	The label notes that hand-muscle weakness may occur in palmar use.
Botox for facial hyperhidrosis	Not established in the current U.S. label.	The label notes eyelid ptosis as a possible site-related concern.
Botox for plantar or other body sites	Not established in the current U.S. label.	Published or clinical use does not create a shared approved indication.

The status table describes one product and one market. It does not establish the approval status of other toxin products or countries. See the current BOTOX prescribing information 🔗.

What Treatment Outcomes Measure

Outcome	What it captures	Interpretation limit
Gravimetric sweat production	Change in the measured mass of sweat over a defined period.	A laboratory reduction does not fully describe daily burden.
Hyperhidrosis Disease Severity Scale	How tolerable sweating is and how much it interferes with daily activity.	It is a patient-reported severity measure, not a product-conversion scale.
Quality of life	Social, occupational, clothing, comfort, and emotional burden.	Improvement depends on site, baseline severity, and follow-up period.
Duration and retreatment	How long benefit persists in the studied product and population.	Duration from one protocol cannot be generalized across products or sites.

The U.S. BOTOX label bases its axillary evidence on randomized, double-blind, placebo-controlled studies using both disease-severity and sweat-production outcomes. A broader systematic review found stronger evidence for axillary botulinum toxin treatment than for palmar and other sites, where evidence and safety characterization were more limited.

Safety Changes by Body Site

Axillary treatment involves intradermal distribution over a sweat-producing field rather than deliberate weakening of a skeletal muscle. Even so, the product’s boxed warning, contraindications, interactions, and general adverse-reaction information remain relevant. The BOTOX axillary trials reported local injection-site effects and non-axillary sweating among the observed reactions.

Other sites introduce different functional questions. Palmar treatment can affect hand strength; facial treatment can affect eyelid position or nearby facial function; plantar treatment raises a different pain and mobility context. These distinctions are anatomical and product-specific, not evidence that one site or brand is universally safer.